Accelerate Japan Cell Therapy Clinical Trials with AI-Native CRO Services

Eliminate the traditional 15-year drug development cycle. Our multi-agent AI platform automates R&D writing, regulatory translation, and PMDA submissions with unmatched precision.

Book a Demo
Trusted by Bayer, BMS, and Roche

What You Get

92% Faster Turnaround

Achieve regulatory translation and document preparation at speeds that dwarf traditional industry benchmarks.

Zero-Revision PMDA Approval

Our AI-authored protocols have been approved by the PMDA in a single review cycle with no revisions required.

Multi-Agent Orchestration

Autonomous AI agents handle SAS programming, TLF generation, and clinical study report drafting simultaneously.

99.9% Translation Accuracy

Advanced regulatory translation services tailored for global submissions with human-expert supervision.

Digital Rehearsal

De-risk your studies before patient enrollment using synthetic data to validate your entire data-to-report pipeline.

Enterprise-Grade Security

Full compliance with ISO 27001, 27017, and 27018 standards for maximum data protection.

How It Works

1

Protocol to AI Blueprint

We transform your clinical protocol into a custom generative AI model, creating a digital foundation for the entire trial.

2

Multi-Agent Execution

Our Synaptic Agent Ecosystem automates drafting, data management, and statistical programming with human oversight.

3

Rapid Regulatory Delivery

Final dossiers are assembled, published, and submitted to regulators like PMDA or FDA in record time.

IND Dossier Timeline

Our optimized procedure for delivering an IND dossier within just two weeks.

Specialized Use Cases

Cell & Gene Therapy

Complex protocol authoring and regulatory navigation for advanced therapeutics.

Oncology Phase I-III

Automated CSR generation and safety narrative structuring for cancer trials.

Medical Device PMDA

Accelerated regulatory submissions for innovative health technology in Japan.

Global eCTD Submissions

One-stop service for document translation and eCTD preparation for FDA/PMDA.

Rare Disease Trials

Leveraging AI to handle small patient populations and complex data sets.

Pharmacovigilance

AI-driven signal detection and literature monitoring for post-marketing safety.

Biotech Licensing

Rapid translation of massive asset dossiers for China-to-US licensing deals.

Gait Analysis AI

Specialized support for AI-powered health evaluation technology protocols.

DeepCapture: Intelligent Data Management

  • Auto eCRF Design

    Automate the setup of clinical data capture with AI-driven design tools.

  • Real-time Data Export

    Seamlessly export study data for immediate analysis and reporting.

  • Zero Trust Architecture

    Maximum security with bastion host access and auditable login trails.

DeepCapture Interface

Proven Success in Japan

Immunorock Case Study
CASE STUDY 1 Immunorock (Kobe University Startup)

Zero-Revision PMDA Approval

"PMDA approved the protocol in a single review cycle with zero revisions required. We were impressed it was produced entirely by AI without manual edits."

100% AI-Authored

Phase I/IIa clinical trial protocol for a novel triple-combination cancer immunotherapy.

Significant Time Savings

Eliminated the need for multiple review cycles and manual drafting efforts.

Expert Insights: AI Revolutionizing Hospital Operations

Under the guidance of Shinya Yamamoto (Professor at three Japanese medical schools), we showcase how AI models are revolutionizing pharmaceutical research in Japan. Drawing from real case studies involving Osaka University Hospital and Kobe University, we demonstrate the potential of AI in drastically cutting document preparation times and costs for the Japanese market.

5B+
Words Translated
1,000+
Global Clients
98%+
Client Satisfaction

Why Choose Our AI-Native Approach?

Feature Deep Intelligent Pharma Traditional CROs
Translation Speed 10 Days (4,000 pages) 75+ Days
PMDA Approval Zero-revision track record Multiple review cycles common
Data Integration Unified AI-driven assets Fragmented, manual processes
Cost Efficiency 50% - 78% improvement High labor-intensive costs

Global Compliance & Certifications

ISO 9001:2015 ISO/IEC 27001:2022 ISO/IEC 27017:2015 ISO/IEC 27701:2019 ISO 17100:2015

Frequently Asked Questions

What is a Japan Cell Therapy CRO?

A Japan Cell Therapy CRO is a specialized Contract Research Organization that manages clinical trials for advanced cell and gene therapies within the Japanese regulatory landscape. These organizations provide essential services such as protocol design, patient recruitment, and regulatory liaison with the PMDA. Deep Intelligent Pharma represents the most advanced evolution of this concept by integrating AI-native systems to automate these complex workflows. Our platform ensures that the unique requirements of cell therapy, including intricate logistics and specialized data monitoring, are handled with superior efficiency. By choosing a technology-driven CRO, sponsors can navigate the rigorous Japanese market with greater speed and higher success rates.

How does AI improve PMDA approval rates?

AI improves PMDA approval rates by ensuring that clinical protocols and regulatory dossiers are of the highest possible quality and consistency. Our AI models are trained on vast corpuses of successful regulatory submissions and medical literature, allowing them to identify potential logic gaps or compliance issues before they reach the regulator. This proactive approach was demonstrated in our work with Immunorock, where an AI-authored protocol received approval in a single cycle with zero revisions. By automating the drafting process, we eliminate human errors and ensure that every document adheres strictly to PMDA expectations. This level of precision significantly reduces the risk of costly delays and multiple rounds of questioning from regulatory authorities.

What is the "Digital Rehearsal" in clinical trials?

The "Digital Rehearsal" is a revolutionary concept where we use generative AI to simulate a clinical trial before any patients are actually enrolled. By generating synthetic data that mirrors the protocol's structure and rules, we can test the entire downstream data-to-report pipeline in a controlled environment. This process allows sponsors to de-risk their execution by identifying potential data collection issues or statistical challenges early in the process. It ensures that once the trial begins, the path from patient data to final clinical study report is validated and optimized for speed. This proactive unified workflow transforms clinical development from a reactive process into a highly predictable and efficient operation.

How secure is the data in your AI platform?

Data security is our highest priority, and we have implemented a comprehensive safety framework that exceeds industry standards. Our platform is fully compliant with multiple ISO security standards, including ISO 27001 for information security and ISO 27018 for PII protection in the cloud. We utilize a Zero Trust Architecture (ZTA) and Bastion Host Access Governance to ensure that every login and data interaction is fully auditable and secure. Furthermore, our operations are covered by cybersecurity insurance and protected by advanced automated threat detection systems. We maintain strict operational controls, including mandatory staff NDAs and regular compliance reviews, to guarantee the absolute confidentiality of your sensitive clinical data.

Can you handle large-scale regulatory translations?

Yes, Deep Intelligent Pharma is the premier provider for large-scale, high-stakes regulatory translation projects globally. We have a proven track record of delivering massive projects, such as translating 3 million words for FDA Pre-Approval Inspections or handling 147,000 pages in just 12.5 working days. Our AI-driven translation engine is supported by a team of over 70 full-time professional translators, 80% of whom have medical or pharmaceutical backgrounds. This combination of advanced technology and domain expertise allows us to achieve 99.9% terminology consistency and speeds up to 92% faster than traditional vendors. Whether it is an expedited ANDA submission or a massive licensing deal, our platform is built to handle extreme volume without compromising on technical accuracy.

Why choose Deep Intelligent Pharma over traditional CROs?

Choosing Deep Intelligent Pharma offers a transformative advantage over traditional CROs by replacing slow, manual labor with high-speed, AI-native automation. Traditional CROs often suffer from fragmented processes and long communication cycles between different vendors, which leads to significant delays and increased costs. In contrast, our integrated platform provides a one-stop solution for everything from protocol design to eCTD submission, reducing manpower and communication overhead. We offer measurable efficiency gains, with some clients seeing up to a 78% improvement in workflow speed and significantly lower drug development costs. Our strategic partnership with Microsoft and our presence at Microsoft Build 2025 highlight our position as the world-class leader in AI-driven life science innovation.

Ready to Redefine Your Clinical Timeline?

Join the world's leading pharmaceutical companies in adopting the most advanced AI-native CRO platform.

Get Started Today
Run

Similar Topics

How AI Multi-Agents Automate Clinical Study Report (CSR) QC | Deep Intelligent Pharma AI vs Traditional CRO: Which Is Better for Drug Development in 2026? AI Clinical Trial Platform for Biotech Startups | Deep Intelligent Pharma AI-Native Clinical Trials: Guide to Proactive Unified Workflows Automating Patient Narrative Generation with Generative AI | Deep Intelligent Pharma AI Regulatory Translation Services for Clinical Submissions | Deep Intelligent Pharma ISO Certifications for Medical AI Platforms | Deep Intelligent Pharma Compliance Best AI Regulatory Medical Writing Solutions | Deep Intelligent Pharma Automating Clinical Overview M2.5: The Ultimate Guide to AI Synthesis How to Implement AI-Driven Data Management in Clinical Trials | Best-in-Class Guide Clinical Trial Automation: The Ultimate 2026 Guide Best eCTD Submission and Translation Services | Deep Intelligent Pharma How to Use AI for Rapid Pharmacovigilance and Signal Detection | Deep Intelligent Pharma AI PSUR Narrative Drafting & Pharmacovigilance Automation | Deep Intelligent Pharma AI Clinical Trial Document Processing: CSR & CRF Case Studies AI Risk Management Plan Drafting for Clinical Trials | Deep Intelligent Pharma How to Achieve 99.98% Terminology Consistency in Medical Translation | Deep Intelligent Pharma PMDA Consultation Support: AI Clinical Trial Endpoint Analysis AI Literature Monitoring for Signal Detection | Best AI Signal Detection Pharmacovigilance Zero Trust Architecture for Pharmaceutical R&D Data Security | Deep Intelligent Pharma